Request Demo

Last update 23 Jan 2025

Exenatide

Last update 23 Jan 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

EXENATIDE SYNTHETIC, Exenatide (JAN/USAN/INN), Exendin-4

+ [20]

Target

GLP-1R

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseRespiratory Diseases

Active Indication

Diabetes Mellitus, Type 2Diabetes MellitusHypertension, Pulmonary

Inactive Indication

Coronary Artery DiseaseDiabetes ComplicationsDiabetes Mellitus, Type 1+ [13]

Originator Organization

Eli Lilly & Co.

Amylin Pharmaceuticals, Inc.

Active Organization

Aerami Therapeutics, Inc.

Icure Pharmaceutical Inc.Eli Lilly Nederland BV

+ [3]

Inactive Organization

AstraZeneca PLC

Intarcia Therapeutics, Inc.

Eli Lilly & Co.

+ [1]

Drug Highest PhaseApproved

First Approval Date

US (28 Apr 2005),

Diabetes Mellitus, Type 2

RegulationOrphan Drug (EU), Priority Review (CN)

Structure/Sequence

Sequence Code 751

Source: *****

351

Clinical Trials associated with Exenatide

NCT02586831

/ WithdrawnPhase 1/2IIT

A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes

To assess whether there is a difference in endogenous insulin secretion, measured as stimulated C-peptide secretion (area under the curve during a 4-hour mixed meal tolerance test), at the 1 year visit, for study subjects receiving combinational therapy versus those receiving placebo. The study will also examine the effect of the proposed treatments on immunological outcomes, specifically proportion of regulatory T cells at the 1 year visit.

Start Date01 Jan 2025

Sponsor / Collaborator

University of Miami

[+1]

NCT05663515

/ RecruitingNot Applicable

EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other non-glucagon like peptide 1 receptor agonists (GLP-1 RA) based glucose lowering drugs (GLDs). Study data will be collected from secondary data sources across 7 European countries. The study will be conducted as a multi-country, long-term, retrospective, observational database study. Initiators of exenatide will be matched to initiators of non-GLP-1 RA based GLDs (comparator group) based on propensity score and calendar period of study entry. All analyses for pancreatic cancer will be conducted in the matched study population using an "intention-to-treat" approach. The study will use information from 8 data sources in 7 European countries (France, Spain, The United Kingdom, Finland, Denmark, Norway, and Sweden). Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide or non-GLP-1 RA based GLDs during the study period, 2006 to 2023, will be included. Exposure to exenatide and non-GLP-1 RA based GLDs will be ascertained from recordings of prescriptions or insurance claims registrations as available in the different data sources. The outcome of pancreatic cancer will be defined as a primary diagnosis of pancreatic cancer during follow-up.

Start Date30 Sep 2024

Sponsor / Collaborator

AstraZeneca PLC

[+1]

NCT06252623

/ RecruitingPhase 1IIT

A Human Laboratory Study of Exenatide for Reducing the Reinforcing Effects of Cocaine

This study will determine the safety and tolerability of exenatide (Bydureon®) as a pharmacotherapy for cocaine use disorder. An inpatient human laboratory study will be conducted in which the self-administration of cocaine, as well as the subjective and physiological effects of cocaine, are evaluated during maintenance on placebo and exenatide.
Although exenatide (Bydureon) is approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes, it has not been approved by the FDA to treat cocaine use; therefore, it is called an investigational drug.

Start Date01 Aug 2024

Sponsor / Collaborator

Baylor College of Medicine

100 Clinical Results associated with Exenatide

100 Translational Medicine associated with Exenatide

100 Patents (Medical) associated with Exenatide

4,196

Literatures (Medical) associated with Exenatide

01 Mar 2025·Journal of Controlled Release

Design, evaluation, and in vitro–in vivo correlation of self-nanoemulsifying drug delivery systems to improve the oral absorption of exenatide

Article

Author: Mota-Santiago, Pablo ; Lind, Tania ; Rades, Thomas ; Venkatasubramanian, Ramakrishnan ; Al-Maghrabi, Passant M ; Alavi, Oscar ; Sassene, Philip Jonas ; Müllertz, Anette ; Kirkensgaard, Jacob J K

The ability to predict the absorption of exenatide (Ex), a GLP-1 analogue, after oral dosing to rats in self-nanoemulsifying drug delivery systems (SNEDDS), using in vitro methods, was assessed. Ex was complexed with soybean phosphatidylcholine (SPC) prior to loading into SNEDDS. A design of experiments (DoE) approach was employed to develop SNEDDS incorporating medium-chain triglycerides (MCT), medium-chain mono- and diglycerides (MGDG), Kolliphor® RH40, and monoacyl phosphatidylcholine. SNEDDS with higher proportions of MGDG and Kolliphor® RH40 demonstrated a 9-fold reduction in droplet size (230 to 26 nm), a 1.5-fold decrease in lipolysis (0.23 to 0.34 mmol of FFA), and a 2-fold enhancement in exenatide protection against proteolysis (73 % to 38 %) compared to those with higher MCT content. Permeability studies in Caco-2 cells showed that SNEDDS with higher proportion of MGDG displayed a 40-fold increase in apparent permeability of FD4, when compared to SNEDDS with higher proportion of MCT. An oral gavage study in rats revealed a 1.8-fold higher absorption of Ex in SNEDDS with a higher proportion of MGDG and Kolliphor®RH40 compared to SNEDDS with higher MCT. These results establish a clear in vitro-in vivo correlation, demonstrating that the selected in vitro methods effectively differentiated formulations with high and low absorption of exenatide after oral dosing in rats.

01 Feb 2025·International Journal of Pharmaceutics

Novel double-layered PLGA microparticles-dissolving microneedle (MPs-DMN) system for peptide drugs sustained release by transdermal delivery

Article

Author: Zhang, Suohui ; Liu, Han ; Gao, Yunhua ; Xu, Bo ; Yang, Guozhong ; Zhou, Zequan

The combination of microparticles (MPs) with dissolving microneedles (DMN) represents a promising transdermal approach for the sustained release of biomacromolecule drug. In this study, we developed a double-layered microparticles-dissolving microneedle (MPs-DMN) system, which strategically concentrates PLGA MPs at the tip of the microneedle to achieve sustained release of peptide drugs through transdermal delivery. We selected exenatide (EXT) as a model peptide drug and established HPLC-UV and UPLC-MS methods for the quantitative analysis of the drug content of MPs-DMN and drug concentrations in plasma. Ultrasonication was utilized in the first step of the double emulsion solvent evaporation method to produce PLGA microparticles, achieving a high drug loading efficiency of 22.76 ± 0.64 %, surpassing the commercial products. The EXT-loaded microparticles were then mixed with 10 % w/v sucrose solution to form the first layer of the microneedle, and the mixture of the base solution was added to form the double-layered dissolving microneedle. Microscopic analysis revealed that the MPs were predominantly concentrated in the upper 50 % of the microneedle body, resulting in an impressive drug delivery efficiency of 92.86 ± 1.62 %. The MPs-DMN patch demonstrated the capability to 238.20 ± 5.79 μg of EXT within a compact area of 0.75 cm², surpassing the capacities reported in existing research. The insertion and dissolution assessments exhibited rapid dissolution, maintaining the MPs as an effective drug reservoir within the skin. Pharmacokinetic assessments indicated that the long half-life (T_1/2) of 466.4 ± 12.2 h and high relative bioavailability of 89.71 % for MPs-DMN. Furthermore, pharmacodynamic studies indicated that the MPs-DMN effectively controlled blood glucose levels below 20 mmol/L in diabetic (db/db) mouse for two weeks. These promising findings suggest that the MPs-DMN system could serve as a viable transdermal delivery method for the prolonged administration of peptide drugs.

01 Feb 2025·Biosensors and Bioelectronics

Rational construction of porous cobalt nanoparticle integrated nitrogen doped hollow carbon nanostructures for peptide agonist exendin-4 biosensing

Article

Author: Medlín, Rostislav ; Kannan, Palanisamy ; Nicolai, Laurent Christophe ; Zhang, Wei ; Minar, Jan ; Procházka, Michal ; Natarajan, Bharathi ; Subramanian, Palaniappan

In this study, we designed a point-of-care (POC) testing electrochemical biosensor using an integrated biosensing assay based on hollow-like nitrogen-doped carbon nanostructures combined with cobalt nanoparticles (Co@HNCNs, Co₃O₄@HNCNs, and CoP@HNCNs). These are functionalized with Anti-Exendin-4 Antibodies (Anti-Ex-4-Abs) and Bovine Serum Albumin (BSA) to create sensitive probes (Co@HNCNs/Anti-Ex-4-Abs/BSA, Co₃O₄@HNCNs/Anti-Ex-4-Abs/BSA, and CoP@HNCNs/Anti-Ex-4-Abs/BSA) for the ultrasensitive detection of exendin-4 (Ex-4), a peptide agonist used in the treatment of type 2 diabetes mellitus (T2DM). Among the cobalt-based carbon nanostructures, the Co₃O₄@HNCNs/Anti-Ex-4-Abs/BSA nanoprobe demonstrated superior ability to specifically recognize Ex-4. This was indicated by a significant decrease in the chronoamperometric (CA) i-t current response, facilitating low-level detection of Ex-4. The nanoprobe was capable of detecting Ex-4 concentrations ranging from 1.0 to 90.0 pM, with a sensitivity of 0.60 μA/pM and a limit of detection (LOD) of 0.46 pM (S/N = 3). Furthermore, the Co₃O₄@HNCNs/Anti-Ex-4-Abs/BSA nanoprobes demonstrated the ability to detect nanomolar levels of Ex-4 in blood serum and urine samples, achieving satisfactory recovery rates of 96-104%. The proposed electrostatic interaction chemistry approach establishes a remarkable platform for constructing a peptide agonist biosensor that is effective for detecting Ex-4 in real human serum and urine samples.

News (Medical) associated with Exenatide

26 Dec 2024

·www.drugs.com

FDA Approves Generic GLP-1 Medicine For Diabetes Treatment

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for people living with Type 2 diabetes. Liraglutide , the generic for Victoza, is similar to semaglutide, the active ingredient in the popular weight-loss drug Ozempic . The FDA supports the development of generic drugs, such as GLP-1s, by funding research and informing industry through guidance, Dr. Iilun Murphy , director of the FDA’s Office of Generic Drugs, said. “Generic drugs provide additional treatment options which are generally more affordable for patients,” she said in a statement released Dec. 23, 2024. “Today’s approval underscores the FDA’s continued commitment to advancing patient access to safe, effective and high-quality generic drug products.” Last month, the agency approved the first generic version in this class of medications with the green lighting of a generic version of Byetta (exenatide) . Experts hope the new approvals will help prevent shortages triggered by demand for injectable weight loss and type 2 diabetes drugs, including semaglutide (Ozempic, Wegovy ) and tirzepatide ( Mounjaro , Zepbound ). Liraglutide is expected to expand access for people managing type 2 diabetes , which affects more than 38 million Americans, according to federal health data. Type 2 diabetes is a chronic condition that occurs when the body does not use insulin well and cannot keep blood sugar at normal levels. It is usually diagnosed in adults, but has been increasingly diagnosed in children and teens. Liraglutide improves blood sugar levels by creating similar effects in the body as GLP-1 in the pancreas, which is often found in insufficient levels in those with type 2 diabetes. The prescribing information for the generic version includes a warning about the increased risk of thyroid C-cell tumors. For this reason, patients who have had, or have family members who have ever had medullary thyroid carcinoma should not use liraglutide, nor should those who have an endocrine system condition called multiple endocrine neoplasia syndrome type 2. The most common side effects reported in the clinical trials for liraglutide injection include nausea, diarrhea, vomiting, decreased appetite, dyspepsia and constipation. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug Approval

26 Dec 2024

·www.drugs.com

FDA Approves Generic GLP-1 Medicine, Liraglutide, (a Victoza Generic), For Diabetes Treatment

THURSDAY, Dec. 26, (2024 HealthDay News) -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for people living with Type 2 diabetes . Liraglutide , the generic for Victoza , is similar to semaglutide, the active ingredient in the popular weight-loss drug Ozempic . The FDA supports the development of generic drugs, such as GLP-1s, by funding research and informing industry through guidance, Dr. Iilun Murphy , director of the FDA’s Office of Generic Drugs, said. “Generic drugs provide additional treatment options which are generally more affordable for patients,” she said in a statement released Dec. 23, 2024. “Today’s approval underscores the FDA’s continued commitment to advancing patient access to safe, effective and high-quality generic drug products.” Last month, the agency approved the first generic version in this class of medications with the green lighting of a generic version of Byetta (exenatide) . Experts hope the new approvals will help prevent shortages triggered by demand for injectable weight loss and type 2 diabetes drugs, including semaglutide (Ozempic, Wegovy ) and tirzepatide ( Mounjaro , Zepbound ). Liraglutide is expected to expand access for people managing type 2 diabetes , which affects more than 38 million Americans, according to federal health data. Type 2 diabetes is a chronic condition that occurs when the body does not use insulin well and cannot keep blood sugar at normal levels. It is usually diagnosed in adults, but has been increasingly diagnosed in children and teens. Liraglutide improves blood sugar levels by creating similar effects in the body as GLP-1 in the pancreas, which is often found in insufficient levels in those with type 2 diabetes. The prescribing information for the generic version includes a warning about the increased risk of thyroid C-cell tumors. For this reason, patients who have had, or have family members who have ever had medullary thyroid carcinoma should not use liraglutide, nor should those who have an endocrine system condition called multiple endocrine neoplasia syndrome type 2. The most common side effects reported in the clinical trials for liraglutide injection include nausea, diarrhea, vomiting, decreased appetite, dyspepsia and constipation. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug Approval

23 Dec 2024

·pipelinereview.com

FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes

SILVER SPRING, MD, USA I December 23, 2024 I Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes as an adjunct to diet and exercise. The FDA approved the first generic in this class of medications last month with the approval of a generic referencing Byetta (exenatide). Liraglutide injection and certain other GLP-1 medications are currently in shortage . The FDA prioritizes assessment of generic drug applications for drugs in shortage to help improve patient access to these medications. “The FDA supports development of complex generic drugs, such as GLP-1s, by funding research and informing industry through guidance as part of our ongoing efforts to increase access to needed medications,” said Iilun Murphy, M.D., director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research. “Generic drugs provide additional treatment options which are generally more affordable for patients. Today’s approval underscores the FDA’s continued commitment to advancing patient access to safe, effective and high-quality generic drug products.” Type 2 diabetes is a chronic condition that occurs when the body does not use insulin well and cannot keep blood sugar at normal levels. It develops over many years and is usually diagnosed in adults, but has been increasingly diagnosed in children, teens and young adults. Liraglutide improves blood sugar levels by creating similar effects in the body as GLP-1 in the pancreas, which is often found in insufficient levels in type 2 diabetes patients. According to the Centers for Disease Control and Prevention, more than 38 million Americans have diabetes, and 90% to 95% of those individuals have type 2 diabetes. The prescribing information for the generic liraglutide injection approved today includes a Boxed Warning to advise health care professionals and patients about the increased risk of thyroid C-cell tumors. For this reason, patients who have had, or have family members who have ever had medullary thyroid carcinoma should not use liraglutide, nor should patients who have an endocrine system condition called multiple endocrine neoplasia syndrome type 2. In addition, people who have a prior serious hypersensitivity reaction to liraglutide or any of the product components should not use liraglutide. Liraglutide also carries warnings about pancreatitis, liraglutide pen sharing, hypoglycemia when used in conjunction with certain other drugs known to cause hypoglycemia including insulin and sulfonylurea, renal impairment or kidney failure, hypersensitivity and acute gallbladder disease. The most common side effects reported in the clinical trials for liraglutide injection include nausea, diarrhea, vomiting, decreased appetite, dyspepsia and constipation. Addressing the challenges related to developing generics and promoting more generic competition is a key part of the FDA’s Drug Competition Action Plan and the agency’s efforts to help increase patient access to medicines. The development of complex drug products such as liraglutide can be more difficult due to their complex active ingredient, formulation or mode of delivery. As a result, many complex drugs lack generic competition. To address this issue and facilitate timely development and approval of needed medications, particularly complex products, the FDA works to clarify regulatory expectations for applicants early in the development process, including through guidance for industry and the pre-ANDA program . These efforts make it more feasible for manufacturers to develop generic drugs and can enhance patient access to treatment by helping make these products more available, allowing patients in the United States to obtain the medicines they need. The FDA granted the approval of generic liraglutide injection to Hikma Pharmaceuticals USA Inc. Please contact the manufacturer for information about the medicine’s availability. Additional Resources: The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. SOURCE: U.S. Food and Drug Administration

Drug Approval

100 Deals associated with Exenatide

External Link

KEGG	Wiki	ATC	Drug Bank
D04121	Exenatide	A10BJ01	DB01276

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	US	AstraZeneca AB	28 Apr 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Preclinical	HU	Eli Lilly & Co.	01 Aug 2002
Diabetes Mellitus, Type 2	Preclinical	HU	Eli Lilly & Co.	01 Aug 2002
Polycystic Ovary Syndrome	Discovery	US	AstraZeneca PLC	22 Mar 2016
Heart Failure	Discovery	FR	AstraZeneca PLC	01 May 2015
Heart Failure	Discovery	FR	Eli Lilly & Co.	01 May 2015
Hyperglycemia	Discovery	FR	AstraZeneca PLC	01 Jan 2015
Hyperglycemia	Discovery	FR	Eli Lilly & Co.	01 Jan 2015
Coronary Artery Disease	Discovery	CZ	Eli Lilly & Co.	01 Jun 2011
Ventricular Dysfunction, Left	Discovery	CZ	Eli Lilly & Co.	01 Jun 2011
Hypoglycemia	Discovery	DE	AstraZeneca PLC	01 Feb 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01107717 (EDICT, CTgov)	Phase 4	Diabetes Mellitus, Type 2	318	exenatide+pioglitazone+metformin (Triple Therapy)	(cgbsjjpmek) = hcfxuhwwux gotvmlbgfn (cqgzyqmipt, umwzslqgvc - gaorbuscze) View more	-	05 Sep 2024
				glargine+metformin+glyburide (Conventional Therapy)	(cgbsjjpmek) = hslcbqkpiu gotvmlbgfn (cqgzyqmipt, vfotdwbmvi - wgiaizcaag) View more
NCT03029351 (1981, CTgov)	Phase 4	Kidney Diseases \| Diabetes Mellitus, Type 2 \| Proteinuria	15	Exenatide Extended Release for Inj Susp 2 MG (Exenatide Extended Release)	ftboeboxrw(ytylalmgdo) = gazvfhssra mayczbbtho (qukjpjbohk, brtpvbhxdw - ciyvbjqmza) View more	-	16 Apr 2024
				Placebo (Placebo)	ftboeboxrw(ytylalmgdo) = lgyheyicxg mayczbbtho (qukjpjbohk, dfmfxudciz - miyhssgoqy) View more
NCT02962492 (CTgov)	Not Applicable	Diabetes Mellitus, Type 1	70	Placebo (Placebo Arm:)	pqnitarjgb(beeyhnogtr) = gbckfsubkx pchyjugwmu (wjjdlsettc, nrpwmathit - purckkkqqg) View more	-	29 Feb 2024
				Dapagliflozin (Dapagliflozin Arm:)	pqnitarjgb(beeyhnogtr) = knkwygzstt pchyjugwmu (wjjdlsettc, ztjzyepfbu - mbsefhnqns) View more
NCT01524705 (FLAT-SUGAR, CTgov)	Phase 4	Diabetes Mellitus, Type 2	102	Insulin Glargine+Metformin+Exenatide	rozjnvzvce(hzrpmbxmpr) = ehjlpnjddj ijfckvorys (qesgaoerag, qnpzbyrjib - ddurgwjkue) View more	-	29 Dec 2023
NCT02621489 (Rebuild study, ESC2023)	Phase 4	Diabetes Mellitus, Noninsulin-Dependent, 2	38	Bydureon	dbyqckffle(yifylkbwwq) = cqzlfkutgh eoxazehwxi (dslnbcotwt ) View more	-	25 Aug 2023
				Standard treatment	dbyqckffle(yifylkbwwq) = fjyxhuepfk eoxazehwxi (dslnbcotwt ) View more
NCT03331289 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	107	Placebo (Placebo)	ivvhtexior(yvagbwtidl) = luvcnnxqct addrqeffia (osywfdvtuq, pckgrkavpe - kgzgmvfvzt) View more	-	24 Jul 2023
				Exenatide (Exenatide)	ivvhtexior(yvagbwtidl) = siiiezmknb addrqeffia (osywfdvtuq, tdhqxepcxe - zfgqdgmumg) View more
NCT02981069 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	90	Dapagliflozin (Dapagliflozin)	pbphaogzhn(irowmsxlci) = swlzwswwaa ofvatgfrey (dlyitfuncb, prjivqomle - prkbaevisf) View more	-	20 Jul 2023
				Placebo (Placebo)	pbphaogzhn(irowmsxlci) = hjajljutnn ofvatgfrey (dlyitfuncb, mtlqiqcpkb - vfoxpuxajz) View more
ADA2023	Not Applicable	Diabetes Mellitus, Type 2	153	exenatide or dulaglutide or liraglutide or semaglutide	(xuinoxzmcp) = fqcljogpwt ctojyopidn (jchgcohlnb )	-	20 Jun 2023
ADA2023	Not Applicable	-	-	Exenatide via RP	jdtzeuxlfe(qqegoioaaz) = jpglowdjnl rfmxbidetv (etushzxddf )	-	20 Jun 2023
				Byetta via endoscopic, transenteric injection	jdtzeuxlfe(qqegoioaaz) = khvdjplrgh rfmxbidetv (etushzxddf )
NCT02251431 (CTgov)	Phase 3	Functional disorder \| Diabetes Mellitus, Type 2 \| Cardio-Renal Syndrome \| Chronic Kidney Diseases	57	BYDUREON (Exenatide-extended Release)	amxqgvdxrh(wynfnsoztc) = fjjjhxptkm fhezqflzik (qhrlmvfcvw, ifedrkwuni - cqdfazrtxi) View more	-	17 May 2023
				Placebo (Placebo)	amxqgvdxrh(wynfnsoztc) = kfdezikotv fhezqflzik (qhrlmvfcvw, zfooivpgov - tbxicomwnw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis